95 related articles for article (PubMed ID: 25314774)
41. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
42. Identification of risk factors in atypical chronic myeloid leukemia.
Breccia M; Biondo F; Latagliata R; Carmosino I; Mandelli F; Alimena G
Haematologica; 2006 Nov; 91(11):1566-8. PubMed ID: 17043019
[TBL] [Abstract][Full Text] [Related]
43. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
44. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
45. [The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse].
Xu LP; Liu KY; Huang XJ; Liu DH; Han W; Chen YH; Wang Y; Liu YR; Qin YZ
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):522-5. PubMed ID: 19112914
[TBL] [Abstract][Full Text] [Related]
46. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
[TBL] [Abstract][Full Text] [Related]
47. The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.
Larfors G; Sandin F; Richter J; Själander A; Stenke L; Lambe M; Höglund M
Eur J Haematol; 2017 Apr; 98(4):398-406. PubMed ID: 28009456
[TBL] [Abstract][Full Text] [Related]
48. Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
Jabbour EJ; Siegartel LR; Lin J; Lingohr-Smith M; Menges B; Makenbaeva D
Leuk Lymphoma; 2019 Mar; 60(3):668-674. PubMed ID: 30124372
[TBL] [Abstract][Full Text] [Related]
49. Increased risk of acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) in a county of Hesse, Germany.
Kolb G; Becker N; Scheller S; Zugmaier G; Pralle H; Wahrendorf J; Havemann K
Soz Praventivmed; 1993; 38(4):190-5. PubMed ID: 8212907
[TBL] [Abstract][Full Text] [Related]
50. Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.
Radivoyevitch T; Hlatky L; Landaw J; Sachs RK
Blood; 2012 May; 119(19):4363-71. PubMed ID: 22353999
[TBL] [Abstract][Full Text] [Related]
51. [An analysis of epidemiological indices of stroke based on the data of a regional population register from 2009 to 2012].
Klochikhina OA; Stakhovskaia LV
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):63-9. PubMed ID: 25042494
[TBL] [Abstract][Full Text] [Related]
52. [Extrapulmonary tuberculosis according to the data of personal registries of new tuberculosis cases].
Karatavykh AA; Borisov SE; Matveeva MV; Belilovskiĭ EM
Tuberk Biolezni Legkih; 2009; (10):17-26. PubMed ID: 20000076
[TBL] [Abstract][Full Text] [Related]
53. Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries.
Lam CJK; Warren JL; Nielsen M; Smith A; Boyd E; Barrett MJ; Mariotto AB
J Natl Cancer Inst Monogr; 2020 May; 2020(55):31-38. PubMed ID: 32412074
[TBL] [Abstract][Full Text] [Related]
54. [Rheumatism in the Russian Federation: statistic and reality].
Folomeeva OM; Benevolenskaia LI
Vestn Ross Akad Med Nauk; 1996; (11):21-4. PubMed ID: 9011275
[TBL] [Abstract][Full Text] [Related]
55. [Epidemiology of stroke in the Russian Federation: results of territory's population registry (2009-2010)].
Stakhovskaia LV; Klochikhina OA; Bogatyreva MD; Kovalenko VV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(5):4-10. PubMed ID: 23739494
[TBL] [Abstract][Full Text] [Related]
56. How I manage Chronic Myeloid Leukemia in 2015.
Kaur V; Adballah AO; Ziang Z
J Ark Med Soc; 2016 Aug; 113(2):43-45. PubMed ID: 30047632
[No Abstract] [Full Text] [Related]
57. Living with CML: is death no longer the end (point)?
White DL; Hughes TP
Blood; 2015 Jul; 126(1):2-4. PubMed ID: 26138535
[No Abstract] [Full Text] [Related]
58. Age at diagnosis of chronic myelogenous leukemia.
Juneja SK; Januszewicz EH
Blood; 1989 Oct; 74(5):1858-9. PubMed ID: 2790210
[No Abstract] [Full Text] [Related]
59. Chronic Respiratory Diseases in the Regions of Northern Russia: Epidemiological Distinctions in the Results of a National Population Study.
Gambaryan MH; Shalnova SA; Deev AD; Drapkina OM
Int J Environ Res Public Health; 2017 Jul; 14(8):. PubMed ID: 28933768
[TBL] [Abstract][Full Text] [Related]
60. [Epidemiology of stroke in Russia].
Gusev EI; Skvortsova VI; Stakhovskaia LV
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Suppl 8):4-9. PubMed ID: 12830512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
